Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 Oct 1:228:115687.
doi: 10.1016/j.ejca.2025.115687. Epub 2025 Aug 5.

Uveal Melanoma UK national guidelines: 2023 update

Thomas J Carter  1 , Jack Broadfoot  2 , Sarah E Coupland  3 , Bertil Damato  4 , Helen Evans  5 , Stephen Fenwick  6 , Leila Khoja  7 , Tracey Krausa  5 , Rachel Lewis  8 , Paul Nathan  9 , Sachin Modi  2 , Guy Negretti  10 , Sukaina Rashid  8 , Joseph J Sacco  11 , Heather Shaw  12 , Karen Sisley  13 , Reta Sowton  14 , Samra Turajlic  15 , Nancy Turnbull  16 , Audrey Woraker  5 , Matthew Wheater  17
Affiliations
Free article
Practice Guideline

Uveal Melanoma UK national guidelines: 2023 update

Thomas J Carter et al. Eur J Cancer. .
Free article

Abstract

UK Guidelines for the management of uveal melanoma (UM) were first published in 2015 using an evidence-based systematic approach. The primary aim of this guideline was to optimise patient care by providing recommendations based on the best available scientific evidence. The resulting guideline reflected the strengths and weaknesses of the available evidence, made recommendations that were clinically impactful around prognostication, surveillance, and treatment for patients with primary lesions and metastatic disease. The guideline development process and content met the standards required by NICE and were ultimately NICE accredited. Here, we present an update to these guidelines, highlighting where practice or treatment has changed to such an extent that the original recommendations are now out of date. Presented here are updated guidelines on molecular and genetic testing, management of metastatic disease and clinical surveillance.

Keywords: Choroidal; Guidelines; Melanoma; UK; UM; Uveal.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: All GDG members completed a Declaration of Interest form prior to attending their first meeting. All interests were declared at the first meeting. It was agreed that members with a commercial interest in any drug or technology under discussion could remain in the room and answer questions from GDG members but were not allowed to participate in the discussion or the formulation of recommendations. Dr. Thomas Carter: Speaker fees from the following companies: BMS, MSD, Regeneron. Institutional grant from MSD. Jack Broadfoot - Nil Prof Sarah Coupland: Advisor to ImmunoCore. Prof Bertil Damato: Immunocore Ltd. Consultant. Consultancy work for AURA and Eckert and Ziegler and Ideaya biosciences. Advisor to CureOM, Ocular Melanoma UK and A Cure in Sight. Helen Evans - Nil Mr Stephen Fenwick: Contributed to AdBoards run by Delcath Systems Inc, and contributed to the Medical Advisory Board of OcuMel UK Leila Khoja – Nil Tracey Krausa – Nil Rachel Lewis - Nil Dr Sachin Modi: Paid consultancy for DELCATH Prof. Paul Nathan: Advisory board member for BMS, Immuncore, Ipsen, Merck, MSD, Novartis, Pfizer, 4SC. TSG member for Novartis & Ipsen studies. Institution has received research funding from Immunocore Guy Negretti – Nil Sukaina Rashid - Nil Dr Joe Sacco: Received honoraria from BMS and Immunocore; received travel and conference expenses from BMS, MSD and Immunocore; participated in paid advisory boards for Immunocore, Delcath, MSD, Amgen and Immuncore. Institution has received research funding from AstraZeneca, BMS and Immunocore. Dr Heather Shaw: Honoraria and fees for speaking at educational meetings, advisory board and travel expenses from BMS/MSD. Payment to department related to conduct of clinical studies – BMS, MSD, Immunocore. Karen Sisley – Nil Reta Sowton – Nil Samra Turajilic – Nil Nancy Turnbull - Nil Dr Matthew Wheater: Speaker fees, consultancy and conference fees from the following companies: BMS, MSD, Delcath Systems. Research funding from BMS, MSD and Delcath systems.

Publication types

LinkOut - more resources